Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.68 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 15/20 | 0.53 |
| ▸ | PPARG | P37231 | 15/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286145 | 1.00 | PTPN1 (0.68) | PTPN1PGRADORA3CHRM1TBXA2R | |
| SCHEMBL6279623 | 1.00 | PTPN1 (0.68) | PTPN1PGRADORA3CHRM1TBXA2R | |
| SCHEMBL6285738 | 1.00 | PTPN1 (0.68) | PTPN1PGRADORA3CHRM1TBXA2R | |
| SCHEMBL6287133 | 1.00 | PTPN1 (0.68) | PTPN1PGRADORA3CHRM1TBXA2R | |
| SCHEMBL6282793 | 1.00 | PTPN1 (0.68) | PTPN1PGRADORA3CHRM1TBXA2R | |
| SCHEMBL6286007 | 1.00 | PTPN1 (0.68) | PTPN1PGRADORA3CHRM1TBXA2R | |
| SCHEMBL6286516 | 0.95 | PTPN1 (0.65) | PTPN1PGRADORA3CHRM1TBXA2R | |
| SCHEMBL6283196 | 0.94 | PTPN1 (0.72) | PTPN1PGRADORA3CHRM1TBXA2R | |
| SCHEMBL6279622 | 0.94 | PTPN1 (0.72) | PTPN1PGRADORA3CHRM1TBXA2R | |
| SCHEMBL6279521 | 0.94 | PTPN1 (0.72) | PTPN1PGRADORA3CHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911468-B2 | Tyrosine phosphatase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1284260-A1 | TYROSINE PHOSPHATASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | PTPRC, PTPN1, PTPRM | PTPN1 2/4885PGR 2273/4885ADORA3 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.